Anatara Lifesciences Limited

Anatara Lifesciences Limited (ASX:ANR) has today undertaken to extend by 12 months the expiry date of 250,000 Options which Anatara issued to the Pork Cooperative Research Centre in 2015.

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that global animal health company, Zoetis Inc. has exercised its option to negotiate a commercial agreement for the worldwide development, distribution and marketing of Detach(R), with terms to be agreed.

Anatara Lifesciences (ASX:ANR) is pleased to release to investors a copy of the presentation for the Gold Coast Investment Showcase (June 21st & 22nd 2017).

Wilsons maintain a BUY rating and $1.66 price target. Anatara's recent stock underperformance has simply reflected a slow quarter for news in the lead-up to a significant inflection point in the 2H.

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide investors with an update on recent progress.

An oral drench to protect piglets from gut infection could soon be available to pig farmers. It's been developed by scientists and is made from pineapples - taking antibiotics out of the food chain.

Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide the Company's Half Yearly Report for the period ended 31 December, 2016.

Anatara Lifesciences Ltd (ASX:ANR) is pleased to announce that it has received a second payment under the exclusive Evaluation and License Option Agreement with the leading global animal health company Zoetis Inc. (NYSE:ZTS) for Detach(TM), Anatara's non-antibiotic anti-infective product.

NDF Research yesterday released its initiation report on Anatara Lifesciences Ltd (ASX:ANR). The report provided a valuation at $2.22 per share base case and $5.94 per share optimistic case using a DCF approach, with a target price of $4.00 per share sitting midpoint of their valuation range.

Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its updated investor presentation.